Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortization of Deferred Charges: 2023-2025

Historic Amortization of Deferred Charges for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$375,000.

  • Compass Therapeutics' Amortization of Deferred Charges fell 34.89% to -$375,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$747,000, marking a year-over-year increase of 65.94%. This contributed to the annual value of -$1.7 million for FY2024, which is 48.82% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Amortization of Deferred Charges is -$375,000, which was down 192.97% from -$128,000 recorded in Q2 2025.
  • Compass Therapeutics' Amortization of Deferred Charges' 5-year high stood at $26,000 during Q1 2025, with a 5-year trough of -$1.0 million in Q2 2023.
  • For the 3-year period, Compass Therapeutics' Amortization of Deferred Charges averaged around -$486,727, with its median value being -$376,000 (2024).
  • The largest annual percentage gain for Compass Therapeutics' Amortization of Deferred Charges in the last 5 years was 106.91% (2025), contrasted with its biggest fall of 34.89% (2025).
  • Over the past 3 years, Compass Therapeutics' Amortization of Deferred Charges (Quarterly) stood at -$812,000 in 2023, then spiked by 66.75% to -$270,000 in 2024, then tumbled by 34.89% to -$375,000 in 2025.
  • Its Amortization of Deferred Charges stands at -$375,000 for Q3 2025, versus -$128,000 for Q2 2025 and $26,000 for Q1 2025.